Yorba Linda, Ca (PRWEB)
May 31, 2017
As part of the SyncD3 webinar series, Thermo Fisher Scientific will sponsor an event where attendees will learn from field scientists and researchers who are working in the ADME/Tox and drug discovery fields and offer an informative discussion on where these areas intersect, the impact on drug discovery and development, and the future of the industry during a live panel discussion with our presenters and you the audience.
High content imaging and analysis offers a robust, high throughput analysis of large numbers of cells with the benefit of the spatial and temporal demarcation afforded by fluorescence microscopy. This webinar will provide an overview of high content imaging platforms, the fluorescent labels required to automate the segmentation of cells and their subcellular domains.
Introduction to the newly developed fluorescent assays from Thermo Fisher Scientific will be provided, with an emphasis on those that provide an indication of cell viability, mechanisms of cell death, proliferation as well as the plethora of reagents that can be used to indicate pre-lethal toxicity. Newly developed phenotypic assays, in particular those used to profile CRISPR-Cas9 edited cells will also be discussed.
The speaker for this webinar will be Dr. Nicholas Dolman, a senior staff scientist from the Biosciences Division at Thermo Fisher Scientific.
Dr. Dolman received a doctorate of molecular and cellular physiology from the University of Liverpool and completed a post-doctoral fellowship at the NIH. He has been with Thermo Fisher Scientific for seven years and is currently a senior staff scientist in research and development. He has led the development…